Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Shares Outstanding (Diluted Average) (2021 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $27.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 1.43% year-over-year to $27.4 million, compared with a TTM value of $27.4 million through Dec 2025, up 1.43%, and an annual FY2025 reading of $27.4 million, up 1.43% over the prior year.
  • Shares Outstanding (Diluted Average) was $27.4 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $27.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $27.4 million in Q4 2025 and bottomed at $26376.0 in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $22.6 million, with a median of $26.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) crashed 99.9% in 2022, then surged 102830.69% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $26.3 million in 2021, then increased by 2.95% to $27.1 million in 2022, then fell by 1.72% to $26.6 million in 2023, then rose by 1.4% to $27.0 million in 2024, then rose by 1.43% to $27.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for ARCT at $27.4 million in Q4 2025, $27.2 million in Q3 2025, and $27.1 million in Q2 2025.